The Indian Pharma Industry Can Do Better Than Conspiracy Theories and Ad Hominem Attacks
Katherine Eban's recently published book Bottle of Lies exposing the state of affairs in the generic pharma industry has received much critical acclaim from most commentators and critics who track the Indian pharmaceutical industry. The Indian industry and its lobbyists, who have rarely been subject to such minute scrutiny by the press, has been predictably lashing out at the book. Too often in the process, they end up making personal attacks on the journalistic integrity of the author without making any attempt to engage with her substantive reporting. One such example is Ashok Madan's recent post , where he accused Eban of having a 'prejudiced mind.' There are others on Twitter, making
Why do you want company’s to do fist fighting with someone who is hell bent to defame India. Engaging with him is a waste of time. He keeps Parroting the same stuff and most importantly why he wants to be a stakeholder in something wherein he has zero stake! Credentials??— Amit Rajan (@arpit971) June 11, 2019
Bottle of Lies
These attacks against Eban's work is in keeping with a playbook of the Indian pharmaceutical industry to deal with its critics. This playbook includes the threat of action for defamation, actually suing critics for defamation, the 'anti-national' argument and lastly to claim a conspiracy theory against the Indian industry. Let me illustrate each of these tactics with an example.
It is an open secret that the regulatory framework in India encourages two different standards of quality for medicines.
In 2012, Dr Chander Gulati, the editor of Monthly Index of Medical Specialties, was sued for criminal defamation, in Bangalore, for writing about a drug called Deanxit which was being sold in India despite being prohibited in Denmark which is the country of its origin. Since then, the safety of Deanxit has been the subject of discussion in a Parliamentary report on the CDSCO; the drug has been banned twice by the health ministry. Both times, bans were quashed by the Karnataka high court, on dubious grounds. I had filed a petition last year before the Delhi high court to get the drug removed from the Indian market and hopefully the sub-committee on DTAB will make such a recommendation soon.
In 2013, when Ranbaxy's plea to seven counts of criminal felony for supplying sub-standard drugs to the US market was publicly reported, some Indian hospitals and pharmacies wanted clarity on their drug supply and asked the then government whether to continue with the purchase of drugs that Ranbaxy sold in India. It is an open secret that the regulatory framework in India encourages two different standards of quality for medicines. One set of manufacturing facilities make 'export' quality; made to comply with CGMP and another, a much lower standard under the purview of Schedule M of the D&C Act for consumption in India. When the flag bearer of the Indian pharma industry was copping with a plea against making Not of Standard Quality (NSQ) drugs for its export market (the USA), these healthcare facilities were acting in the best interest of their patients. The official stance of the Indian government and the pharma lobby groups was to float a conspiracy theory, which alleged that the Indian pharmaceutical industry was being targeted by the American government to protect the American industry from competition from the industry in India.
One set of manufacturing facilities make 'export' quality; made to comply with CGMP and another, a much lower standard under the purview of Schedule M of the D&C Act for consumption in India.
In 2014, when a group of academics in North America, including Amir Attaran at University of Ottawa, published a working paper on the issue of quality of drugs sold by the same Indian companies to different countries, the Indian government threatened to sue the academics for defaming the Indian industry. As lawyer and scholar Gautam Bhatia explained at the time, such action was legally untenable.
In 2015, when a whistleblower at GVK Bio risked his life to expose the wrongdoings at the facility, the government and industry sold the media a story of a love story that had gone wrong.
In 2016, when I approached the Supreme Court through a PIL, the drug controller general of India basically insinuated that I was an 'anti-national' because I sought to question the quality of Indian medicines before an Indian court. Since the court dismissed my petition saying my arguments were academic, the government of India has made bioequivalence and stability testing compulsory - I had raised both these issues in my PIL. After a second petition of mine was admitted by the Delhi high court, two of the drugs I had targeted in the original PIL before the Supreme Court have been banned or withdrawn by the companies in question. One can judge for themselves why these manufacturers would rather withdraw profitable drugs than litigate against my petition in the court. I had the best interests of patients in India at heart in both cases.
The drug controller general of India basically insinuated that I was an 'anti-national' because I sought to question the quality of Indian medicines before an Indian court. Photo: Reuters/Srdjan Zivulovic/Files
I am sure there are more instances of others who have spoken up against the industry being painted as anti-national and libellous by Indian pharma lobbyists and the government. At the end of the day, I think it is up to journalists and editors to separate sense from nonsense and ensure that crucial issues do not get drowned out by these personal attacks and threats of defamation. We have seen this playbook in action way too many times before, and all I can say is it is all too predictable.
Arguments that generic drugs make healthcare affordable, that the Indian industry played an important role in providing access to life-saving medicines during the HIV epidemic etc. are used to divert attention away from the issue at hand, quality of our drug supply.
Of late, there is one more tactic that has been added to the playbook, distraction. When unable to counter facts objectively, cheerleaders for the industry point to the good that the Indian pharma industry has done for patients worldwide. Arguments that generic drugs make healthcare affordable, that the Indian industry played an important role in providing access to life-saving medicines during the HIV epidemic etc. are used to divert attention away from the issue at hand, quality of our drug supply. Another tactic used to divert attention is to point to the wrongdoing within Big Pharma (and there is much to talk about off-label-prescription, financial fraud etc.) and somehow justify that everyone does it, therefore, it is not a big deal.
None of this is relevant to the issue being debated. In fact, the book celebrates the achievements of the Indian pharma industry for precisely this; that the industry played a key role in making life-saving medicines affordable to patients globally. The thesis of the book is that when patients with meagre means are knowingly sold substandard, therapeutically ineffective medication, it does no one any favours. Especially in a country like India, where systems to study and document long term effects of poor quality medicines are sparse at best, addressing structural issues within our supply chain, like encouraging two different standards of quality when life-saving medication are concerned, fixing accountability for ensuring compliance with standards for sterility, hygiene, record-keeping etc. is an important debate to have.
When the industry performs poorly, it not only affects the interests of the shareholders who invest but also prospects of hundreds of thousands of young people who would have otherwise seen gainful employment in this area.
What the regulators, the industry lobby and its cheerleaders fail to recognise is that their tactics, which they have employed since the modus operandi of the industry became public in May 2013 have not stemmed the industry's prospects for a precipitous decline. This industry, which was once called a sunrise industry along with Information Technology because it earned so much foreign exchange for the country, has been declining for the last five years. When the industry performs poorly, it not only affects the interests of the shareholders who invest but also prospects of hundreds of thousands of young people who would have otherwise seen gainful employment in this area. If the tactics being employed by the industry to address what it sees as a 'PR Problem' have not reversed this decline in the industry's fortunes over the last five years, how wise is it I wonder to continue to double down on the approach they have chosen to respond with?
For those who wish the Indian pharma industry to regain its lost glory of being the 'pharmacy to the world,' let us debate facts, not opinions. Whataboutery plays only so well with emotions, at the end of the day, it is facts and the situation on the ground that determines whether we continue to support this fallacy that our drug supply in India is only 3% NSQ.
This article was originally published on Observer Research Foundation (ORF)